Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319


Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer.

Lee KS, Kwak Y, Ahn S, Shin E, Oh HK, Kim DW, Kang SB, Choe G, Kim WH, Lee HS.

Cancer Immunol Immunother. 2017 Jul;66(7):927-939. doi: 10.1007/s00262-017-1999-6. Epub 2017 Apr 12.


PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.

Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M.

Mod Pathol. 2016 Sep;29(9):1104-12. doi: 10.1038/modpathol.2016.95. Epub 2016 May 20.


Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.

Nakaji Y, Oki E, Nakanishi R, Ando K, Sugiyama M, Nakashima Y, Yamashita N, Saeki H, Oda Y, Maehara Y.

J Cancer Res Clin Oncol. 2017 Jan;143(1):151-160. doi: 10.1007/s00432-016-2275-4. Epub 2016 Sep 26.


Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.

Kim JH, Park HE, Cho NY, Lee HS, Kang GH.

Br J Cancer. 2016 Aug 9;115(4):490-6. doi: 10.1038/bjc.2016.211. Epub 2016 Jul 12.


Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.

Korehisa S, Oki E, Iimori M, Nakaji Y, Shimokawa M, Saeki H, Okano S, Oda Y, Maehara Y.

Int J Cancer. 2018 Feb 15;142(4):822-832. doi: 10.1002/ijc.31107. Epub 2017 Oct 31.


High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients with colorectal cancer.

Markovic S, Antic J, Dragicevic N, Hamelin R, Krivokapic Z.

J Mol Histol. 2012 Apr;43(2):137-43. doi: 10.1007/s10735-011-9387-6. Epub 2012 Jan 1.


Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.

Bettstetter M, Dechant S, Ruemmele P, Grabowski M, Keller G, Holinski-Feder E, Hartmann A, Hofstaedter F, Dietmaier W.

Clin Cancer Res. 2007 Jun 1;13(11):3221-8.


CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.

Lee SJ, Jun SY, Lee IH, Kang BW, Park SY, Kim HJ, Park JS, Choi GS, Yoon G, Kim JG.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1005-1014. doi: 10.1007/s00432-018-2620-x. Epub 2018 Mar 8.


Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.

Kim JH, Kang GH.

World J Gastroenterol. 2014 Apr 21;20(15):4230-43. doi: 10.3748/wjg.v20.i15.4230. Review.


Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.

Seppälä TT, Böhm JP, Friman M, Lahtinen L, Väyrynen VM, Liipo TK, Ristimäki AP, Kairaluoma MV, Kellokumpu IH, Kuopio TH, Mecklin JP.

Br J Cancer. 2015 Jun 9;112(12):1966-75. doi: 10.1038/bjc.2015.160. Epub 2015 May 14.


Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.

Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M.

Gastroenterology. 2008 Apr;134(4):988-97. doi: 10.1053/j.gastro.2008.01.015. Epub 2008 Jan 11.


Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.

Ooki A, Akagi K, Yatsuoka T, Asayama M, Hara H, Takahashi A, Kakuta M, Nishimura Y, Yamaguchi K.

J Surg Oncol. 2014 Dec;110(8):982-8. doi: 10.1002/jso.23755. Epub 2014 Aug 22.


BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.

Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, Rosty C, Young JP, Win AK, Hopper JL, Crook A, von Deimling A, Jenkins MA, Buchanan DD, Gill AJ.

Am J Surg Pathol. 2013 Oct;37(10):1592-602. doi: 10.1097/PAS.0b013e31828f233d.


Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.

Cho J, Lee J, Bang H, Kim ST, Park SH, An JY, Choi MG, Lee JH, Sohn TS, Bae JM, Kang WK, Kim S, Kim KM.

Oncotarget. 2017 Feb 21;8(8):13320-13328. doi: 10.18632/oncotarget.14519.


Molecular profile and copy number analysis of sporadic colorectal cancer in Taiwan.

Lin CH, Lin JK, Chang SC, Chang YH, Chang HM, Liu JH, Li LH, Chen YT, Tsai SF, Chen WS.

J Biomed Sci. 2011 Jun 7;18:36. doi: 10.1186/1423-0127-18-36.


Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.

Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A.

J Pathol. 2011 Nov;225(3):336-43. doi: 10.1002/path.2879. Epub 2011 Jun 9.


Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ.

Ann Oncol. 2014 May;25(5):1032-8. doi: 10.1093/annonc/mdu100. Epub 2014 Feb 27.


Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.

Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, Matulonis UA, Konstantinopoulos PA.

JAMA Oncol. 2015 Dec;1(9):1319-23. doi: 10.1001/jamaoncol.2015.2151.


Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic.

Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S.

Br J Surg. 2004 Apr;91(4):469-75.


Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.

Xiao X, Dong D, He W, Song L, Wang Q, Yue J, Xie L.

Gynecol Oncol. 2018 Apr;149(1):146-154. doi: 10.1016/j.ygyno.2018.02.009. Epub 2018 Mar 1.


Supplemental Content

Support Center